Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia

Seminars in Hematology

Volumn 44, Issue 4, 2007, Pages 246-251

  Dreger, Peter ^a   Brand, Ronald ^b   Michallet, Mauricette ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTHRACYCLINE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE;

ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE CONTROL; DRUG MEGADOSE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; METASTASIS; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE; TREATMENT INDICATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; CARMUSTINE; COMBINED MODALITY THERAPY; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; EVIDENCE-BASED MEDICINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MELPHALAN; NEOPLASM, RESIDUAL; NEOPLASMS, SECOND PRIMARY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 35349007997     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2007.08.008     Document Type: Article

References (35)

1. Gribben J.G., Neuberg D., Soiffer R.J., Fisher D.C., Schlossman R., Alyea E.P., et al. Autologous versus allogeneic bone marrow transplantation for patients with poor prognosis CLL. Blood 92 (1998) 322a (abstr, suppl 1)
2. Gribben J.G., Zahrieh D., Stephans K., Bartlett-Pandite L., Alyea E.P., Fisher D.C., et al. Autologous and allogeneic stem cell transplantation for poor risk chronic lymphocytic leukemia. Blood 106 (2005) 4389-4396
3. Esteve J., Montserrat E., Dreger P., Meloni G., Pavletic S., Catovsky D., et al. Stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL): Outcome and prognostic factors after autologous and allogeneic transplants. Blood 98 (2001) 482a (abstr, suppl 1)
4. Jantunen E., Itala M., Siitonen T., Juvonen E., Koivunen E., Koistinen P., et al. Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: The Finnish experience. Bone Marrow Transplant 37 (2006) 1093-1098
5. Michallet M., van Biezen A., Bandini G., Carreras E., Cornelissen J., Dreger P., et al. Analysis of prognostic factors on the outcome of autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Blood 98 (2001) 859a (abstr)
6. Dreger P., Stilgenbauer S., Busch R., Greinix H., Hensel M., Hertenstein B., et al. Good efficacy but relevant toxicity of early sequential high-dose therapy in genetically poor-risk CLL: Results from the GCLLSG CLL3 protocol. Onkologie 28 suppl 3 (2005) 29
7. Milligan D.W., Fernandes S., Dasgupta R., Davies F.E., Matutes E., Fegan C.D., et al. Autografting for younger patients with chronic lymphocytic leukaemia is safe and achieves a high percentage of molecular responses. Results of the MRC pilot study. Blood 105 (2005) 397-404
8. Milligan D.W., Kochethu G., Dearden C., Matutes E., MacConkey C., and Catovsky D. High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council pilot of autografting in chronic lymphocytic leukaemia. Br J Haematol 133 (2006) 173-175
9. Dreger P., Ritgen M., Böttcher S., Schmitz N., and Kneba M. The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: Is achievement of molecular remission worthwile?. Leukemia 19 (2005) 1135-1138
10. Moreno C., Villamor N., Esteve J., Colomer D., Bosch F., Campo E., et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 107 (2006) 4563-4569
11. Zenz T., Ritgen M., Dreger P., Krober A., Barth T.F., Schlenk R., et al. Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 108 (2006) 2127-2130
12. Montillo M., Tedeschi A., Miqueleiz S., Veronese S., Cairoli R., Intropido L., et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 24 (2006) 2337-2342
13. Dreger P., Corradini P., Kimby E., Michallet M., Milligan D., Schetelig J., et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: The EBMT transplant consensus. Leukemia 21 (2007) 12-17
14. Dreger P., Stilgenbauer S., Benner A., Ritgen M., Kroeber A., Kneba M., et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: A risk-matched analysis based on the VH gene mutational status. Blood 103 (2004) 2850-2858
15. Ritgen M., Lange A., Stilgenbauer S., Dohner H., Bretscher C., Bosse H., et al. Unmutated immunoglobulin variable heavy chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 101 (2003) 2049-2053
16. Michallet M., Chevret S., Brand R., van Biezen A., Levy V., Dreger P., et al. Autologous and allogeneic hematopoietic stem cell tranplantations versus conventional chemotherapy in chronic lymphocytic leukemia (CLL): An EBMT and French CLL Cooperative Group study. Blood 100 (2003) 39a (abstr)
17. Leporrier M., Chevret S., Cazin B., Boudjerra N., Feugier P., Desablens B., et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98 (2001) 2319-2325
18. Johnson S., Smith A.G., Löffler H., Ösby E., Juliusson G., Emmerich B., et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin,and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 347 (1996) 1432-1438
19. Rai K.R., Peterson B.L., Appelbaum F.R., Kolitz J., Elias L., Shepherd L., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1750-1757
20. Eichhorst B.F., Busch R., Hopfinger G., Pasold R., Hensel M., Steinbrecher C., et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood 107 (2006) 885-891
21. Flinn I.W., Neuberg D.S., Grever M.R., Dewald G.W., Bennett J.M., Paietta E.M., et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup trial E2997. J Clin Oncol 25 (2007) 793-798
22. Byrd J.C., Rai K., Peterson B.L., Appelbaum F.R., Morrison V.A., Kolitz J., et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105 (2005) 49-53
23. Keating M.J., O'Brien S., Albitar M., Lerner S., Plunkett W., Giles F., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 4079-4088
24. Wendtner C.M., Ritgen M., Schweighofer C.D., Fingerle-Rowson G., Campe H., Jager G., et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18 (2004) 1093-1101
25. Niscola P., Del Principe M.I., Maurillo L., Venditti A., Buccisano F., Piccioni D., et al. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia 19 (2005) 1840-1841
26. Dreger P., van Biezen A., Brukx K., Boogaerts M., Michallet M., Milligan D., et al. Treatment-related MDS/AML after autologous stem cell transplantation for chronic lymphocytic leukemia (CLL): An EBMT survey. Blood 106 (2006) 326a-327a
27. Morrison V.A., Rai K.R., Peterson B.L., Kolitz J.E., Elias L., Appelbaum F.R., et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: Results of an intergroup study, Cancer and Leukemia Group B 9011. J Clin Oncol 20 (2002) 3878-3884
28. Tam C.S., Seymour J.F., Prince H.M., Kenealy M., Wolf M., Januszewicz E.H., et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 91 (2006) 1546-1550
29. Ljungman P., Urbano-Ispizua A., Cavazzana-Calvo M., Demirer T., Dini G., Einsele H., et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Definitions and current practice in Europe. Bone Marrow Transplant 37 (2006) 439-449
30. Lamanna N., Kalaycio M., Maslak P., Jurcic J.G., Heaney M., Brentjens R., et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 24 (2006) 1575-1581
31. Hainsworth J.D., Litchy S., Barton J.H., Houston G.A., Hermann R.C., Bradof J.E., et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21 (2003) 1746-1751
32. O'Brien S., Moore J.O., Boyd T.E., Larratt L.M., Skotnicki A., Koziner B., et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 25 (2007) 1114-1120
33. Kay N.E., Rai K.R., and O'Brien S. Chronic lymphocytic leukemia: current and emerging treatment approaches. Clin Adv Hematol Oncol 4 (2006) 1-12
34. Bruno B., Rotta M., Patriarca F., Mordini N., Allione B., Carnevale-Schianca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356 (2007) 1110-1120
35. Delgado J., Thomson K., Russell N., Ewing J., Stewart W., Cook G., et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: A British Society of Blood and Marrow Transplantation study. Blood 107 (2006) 1724-1730